| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Obstetrics and Gynecology, Fukui Medical University
Matsuoka-Cho, Yoshida-Gun, Fukui-ken 910-1103, Japan.
2 Department of Radiology, Fukui Medical University Matsuoka-Cho, Yoshida-Gun,
Fukui-ken 910-1103, Japan.
3 Departments of Neurosurgery and the Biomedical Imaging Research Center, Fukui
Medical University Matsuoka-Cho, Yoshida-Gun, Fukui-ken 910-1103, Japan.
OBJECTIVE. The purpose of this study was to determine whether the addition of positron emission tomography (PET) with the radiotracer FDG to cross-sectional imaging, such as CT, increases accuracy in the detection of tumor spread.
SUBJECTS AND METHODS. Fifteen patients who were thought to have ovarian cancer on the basis of the results of physical examination, sonography findings, and level of serum cancer antigen 125 were enrolled over an 11-month period. After screening, patients underwent two imaging examinations—abdominopelvic CT and whole-body FDG PET— within 2 weeks before surgery. Also before surgery, staging accuracy was assessed separately using CT with or without FDG PET (which was based on modifications of the International Federation of Gynecology and Obstetrics [FIGO] criteria). The results of the histology and surgery findings were used to assess the accuracy of the scanning findings.
RESULTS. Staging revealed stage III disease in seven patients (IIIC, n = 6; IIIB, n = 1), stage II in three (IIC, n = 2; IIB, n = 1), and stage I in five (IC, n = 3; IA, n = 2), according to the FIGO criteria. Although CT staging correlated with postoperative staging in eight (53%) of 15 patients, consensus evaluation of CT with FDG PET staging improved correlation with postoperative staging in 13 (87%) of 15 patients.
CONCLUSION. The addition of FDG PET to CT increases accuracy in staging of ovarian cancer.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Tsujikawa, Y. Yoshida, T. Mori, T. Kurokawa, Y. Fujibayashi, F. Kotsuji, and H. Okazawa Uterine Tumors: Pathophysiologic Imaging with 16{alpha}-[18F]fluoro-17{beta}-estradiol and 18F Fluorodeoxyglucose PET--Initial Experience Radiology, August 1, 2008; 248(2): 599 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yoshida, T. Kurokawa, Y. Sawamura, A. Shinagawa, T. Tsujikawa, H. Okazawa, T. Tsuchida, Y. Imamura, N. Suganuma, and F. Kotsuji Comparison of 18F-FDG PET and MRI in Assessment of Uterine Smooth Muscle Tumors J. Nucl. Med., May 1, 2008; 49(5): 708 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Suzuki, Y. Nakamoto, T. Terauchi, M. Kawamoto, Y. Okumura, Y. Suzuki, T. Sato, N. Takahashi, J. Lee, M. Senda, et al. Inter-observer Variations in FDG-PET Interpretation for Cancer Screening Jpn. J. Clin. Oncol., August 18, 2007; (2007) hym064v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pandit-Taskar Oncologic Imaging in Gynecologic Malignancies J. Nucl. Med., November 1, 2005; 46(11): 1842 - 1850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Subhas, P. V. Patel, H. K. Pannu, H. A. Jacene, E. K. Fishman, and R. L. Wahl Imaging of Pelvic Malignancies with In-Line FDG PET-CT: Case Examples and Common Pitfalls of FDG PET RadioGraphics, July 1, 2005; 25(4): 1031 - 1043. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
